TG Therapeutics Has Spent Itself Into Profitability Without Anyone Noticing

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

TG Therapeutics reports before the market open, meaning Day 0 captures the first full trading session where investors react to results, and Day +1 reflects follow-through sentiment.

TGTX exhibits high volatility around earnings, with an average absolute Day 0 move of 11.24% and an average Day 0 range of 13.34%. The most recent report on August 3, 2026 saw the stock drop 11.26% on Day 0 despite a revenue beat, as investors focused on the steep earnings miss and elevated spending. The prior quarter (May 6, 2026) delivered a strong 16.26% Day 0 gain as the company raised guidance and Q1 results exceeded expectations.

The historical pattern shows TGTX is prone to sharp moves in either direction depending on whether results and guidance surprise positively or negatively. The September 2025 report that included the massive EPS beat saw only a 3.13% decline on Day 0, suggesting the market looked through the one-time gain, while the May 2025 and August 2025 reports both triggered double-digit declines (13.26% and 17.99%, respectively) on disappointing profitability.

Day +1 moves average 3.66%, indicating some follow-through but typically less dramatic than the initial reaction. Investors should expect a double-digit percentage swing on earnings day, with direction hinging on whether the company can beat the $0.37 EPS estimate and provide confidence that operating expenses are coming under control relative to revenue growth.

Part 2.2: Options Market Expected Move

The options market is pricing a 12.23% expected move (approximately $7.31) by the November 20 expiration, slightly above the 11.24% average historical Day 0 move. This suggests options traders are anticipating volatility in line with—or modestly higher than—the stock's typical earnings reaction, reflecting uncertainty around whether TGTX can reverse its recent string of misses and demonstrate improving profitability alongside continued BRIUMVI revenue strength.

Part 3: What Analysts Are Saying

Analysts maintain a bullish stance on TGTX, with a consensus that has improved over the past month. The current breakdown shows 7 Strong Buys, 0 Moderate Buys, 1 Hold, 1 Moderate Sell, and 0 Strong Sells, yielding an average recommendation of 4.44 on the 5-point scale. One month ago, the mix was 6 Strong Buys, 0 Moderate Buys, 2 Holds, 1 Moderate Sell, and 0 Strong Sells with an average of 4.22, indicating the recent shift reflects one analyst upgrading from Hold to Strong Buy.

The mean price target of $64.38 implies approximately 7.6% upside from the current price of $59.83, with a wide range from a low of $21.00 to a high of $86.00. The $21 low target comes from a bearish outlier (Bank of America Securities' Underperform rating), while the $86 high reflects B. Riley's bullish view on BRIUMVI's multi-billion-dollar revenue potential. The broad dispersion underscores the debate over whether TGTX can successfully scale profitably in a competitive market or whether single-asset risk and execution challenges will limit upside.

The improved sentiment trend suggests analysts are gaining confidence following the company's repeated upward revenue guidance revisions and progress on pipeline catalysts, even as near-term earnings remain under pressure. The consensus view is that BRIUMVI's commercial trajectory supports a Buy rating, but the modest implied upside to the mean target indicates much of the optimism is already reflected in the stock's recent rally—shares are up significantly year-to-date and trading near 52-week highs.

Part 4: Technical Picture

TGTX is technically well-positioned heading into earnings, with the stock trading at $59.83 and sitting above its 10-day ($58.80), 20-day ($56.52), 50-day ($55.80), 100-day ($54.56), and 200-day ($44.53) moving averages. The stock is just slightly below the 5-day moving average ($60.03), suggesting a minor near-term pullback from recent highs but an intact intermediate and longer-term uptrend.

The Barchart Technical Opinion shows strong and improving momentum. The signal currently stands at 100% Buy, up from 88% Buy last week and 56% Buy last month, indicating accelerating bullish sentiment as the stock has pushed to new highs.

Timeframe Analysis:

• Short-term (100% Buy): Maximum bullish signal indicates strong near-term momentum and positive technical setup heading into the earnings event
• Medium-term (100% Buy): Equally strong reading confirms the intermediate trend remains firmly positive with no signs of consolidation or weakening
• Long-term (100% Buy): Maximum bullish signal across all timeframes reflects the stock's sustained uptrend over the past year, with the 200-day moving average providing strong support

Trend Characteristics: The combination of Strong strength and Average direction suggests TGTX is in a robust uptrend with solid momentum, though not yet in an overextended or parabolic phase. This setup is generally supportive for holding through earnings, though the strong technical position also means the stock has less downside cushion if results disappoint.

The stock's position well above all major moving averages and the uniformly bullish technical signals across all timeframes indicate strong momentum heading into the November 9 report. However, the recent consolidation just below the 5-day moving average and the stock's proximity to 52-week highs suggest limited near-term upside is already priced in. The technical setup is supportive but leaves TGTX vulnerable to a sharp pullback if the company delivers another earnings miss or fails to provide confidence on the path to sustained profitability. Key support on any disappointment would likely come at the 20-day moving average around $56.50, with stronger support at the 50-day near $55.80.